帕罗西汀联合奎硫平治疗躯体形式障碍的疗效观察  

Comparison study of paroxetine and paroxetine combined with quetiapine in treatment of somatoform disorders

作　　者：谭伟[1] 饶世雄[1] 

机构地区：[1]自贡市精神卫生中心,四川自贡643020

出　　处：《四川医学》2011年第5期719-720,共2页Sichuan Medical Journal

摘　　要：目的探讨帕罗西汀合并奎硫平治疗躯体形式障碍的疗效及安全性。方法 70例躯体形式障碍患者随机分为两组,研究组以帕罗西汀合并奎硫平进行治疗,对照组单用帕罗西汀治疗,疗程均为8周。治疗前与治疗第2、8周采用症状自评量表(SCL-90)、汉密尔顿抑郁量表(HAMD)评定临床疗效,不良反应量表(TESS)评定不良反应。结果治疗后两组SCL-90,HAMD评分较治疗前减少,差异有统计学意义(P<0.01)。8周末研究组有效率88.2%,对照组有效率54.5%,两组差异有统计学意义(P<0.05)。并且在治疗2周末研究组较对照组见效快,差异有统计学意义(P<0.05)。两组不良反应均表现较轻,大多出现在治疗早期,经对症治疗逐渐缓解。结论帕罗西汀合并奎硫平治疗躯体形式障碍较单用帕罗西汀疗效好,起效快,且不增加不良反应。Objective To study the clinical effects and safety of paroxetine combined with quetiapine in treatment of somatoform disorders.Methods 70 patients were assigned to paroxetine（control group）and paroxetine combined with quetiapine（study group）.and treated for 8 weeks.Before treatment and at the ends of the 2th and 8th week after treatment,the clinical effects and side effects were assessed with SCL-9O.HAMD.TESS.Results The score of SCL-90 and HAMD after the treatment of the study group and control group were lower than before treatment.which had a significant difference（P0.01）.At the end of 8th week,effective rates of the study group and control group were respectivly 88.2% and 55.9%,which had a significant difference（P0.05）.There was difference in the effective time of drugs of the two groups（P0.05）,Side effects of both the two groups were milder.most occurred in the initial stage of treatment and gradually remitted via expectant treatment.Conclusion Paroxetine combined with（1uetiapine in treatment of somatoform disorders takes effects better and faster than single paroxetine and does′t increase side effects.

关 键 词：帕罗西汀 奎硫平 躯体形式障碍 不良反应 

分 类 号：R749.7[医药卫生—神经病学与精神病学]